Skip to main content
Premium Trial:

Request an Annual Quote

Motif BioSciences Closes $1.8M Financing; Funds Will Support Persian Gulf Genetics Program

NEW YORK, March 2 (GenomeWeb News) - Motif BioSciences announced today it has completed a $1.9-million financing round.

 

$500,000 of the financing was from lead investor Amphion and was announced in January. The completed financing was oversubscribed, Motif said in a statement.

 

The funding will support Motif's sample collection and analysis of two sets of genetic data from the Persian Gulf.

 

Motif BioSciences is a population genetics company using genetic data from the Persian Gulf region. It is headquartered in the US and UK and is 47-percent owned by Amphion.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.